(Q43963774)

English

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.

scientific article published in April 2002

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

F Maloisel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

A Guerci

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D Guyotat

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M Michallet

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J Reiffers

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

G Tertain

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M Blanc

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

F Bauduer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J Brière

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J F Abgrall

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

B Pegourie-Bandelier

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

E Solary

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

N Cambier

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D Coso

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J P Vilque

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M Delain

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J L Harousseau

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

P Rousselot

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

K Belhadj

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

P Morice

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J Attal

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

M Chabin

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

C Chastang

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

J Guilhot

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

F Guilhot

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

France Intergroupe des Leucémies Myéloïdes Chroniques

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 April 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

573-580

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11960335%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetic Remissions in Chronic Myelogenous Leukemia Using Interferon Alpha-2a and Hydroxyurea with or without Low-Dose Cytosine Arabinoside.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402433

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43963774&oldid=2206361362"